ARDELYX, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ARDELYX, INC. (ARDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $9.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-19
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $9.60M, a 51.02% decline from fiscal 2024.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $19.60M, a 1681.82% increase from fiscal 2023.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.10M, a 3566.67% increase from fiscal 2022.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $30.00K, a 98.24% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $9.60M 10-K · filed 2026-02-19 |
| 2024-12-31 | $19.60M 10-K · filed 2026-02-19 |
| 2023-12-31 | $1.10M 10-K · filed 2026-02-19 |
| 2022-12-31 | $30.00K 10-K · filed 2025-02-20 |
| 2021-12-31 | $1.70M 10-K · filed 2024-02-22 |
| 2020-12-31 | $2.70M 10-K · filed 2023-03-02 |
| 2019-12-31 | $400.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |